Asian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis
Issued Date
2024-12-01
Resource Type
eISSN
27723747
Scopus ID
2-s2.0-85209561012
Journal Title
JACC: Asia
Volume
4
Issue
12
Start Page
885
End Page
897
Rights Holder(s)
SCOPUS
Bibliographic Citation
JACC: Asia Vol.4 No.12 (2024) , 885-897
Suggested Citation
Yap J., Hayashida K., Lee M.K.Y., Stub D., Hon J.K.F., Ho K.W., Lo S., Seth A., Kim H.S., Wongpraparut N., Nguyen Q.N., Dy T.C., Chandavimol M., Ewe S.H., Yin W.H., Lee Y.T., Tay E.L., Poon K., Chen M., Chui A., Lam S.C.C., Rao R.S., Izumo M., Nair R., Tang G.H., Tabata M., Yahaya S.A., Sin K.Y., Park D.W., Wang J., Chieh J.T.W. Asian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis. JACC: Asia Vol.4 No.12 (2024) , 885-897. 897. doi:10.1016/j.jacasi.2024.10.001 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102189
Title
Asian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis
Author(s)
Yap J.
Hayashida K.
Lee M.K.Y.
Stub D.
Hon J.K.F.
Ho K.W.
Lo S.
Seth A.
Kim H.S.
Wongpraparut N.
Nguyen Q.N.
Dy T.C.
Chandavimol M.
Ewe S.H.
Yin W.H.
Lee Y.T.
Tay E.L.
Poon K.
Chen M.
Chui A.
Lam S.C.C.
Rao R.S.
Izumo M.
Nair R.
Tang G.H.
Tabata M.
Yahaya S.A.
Sin K.Y.
Park D.W.
Wang J.
Chieh J.T.W.
Hayashida K.
Lee M.K.Y.
Stub D.
Hon J.K.F.
Ho K.W.
Lo S.
Seth A.
Kim H.S.
Wongpraparut N.
Nguyen Q.N.
Dy T.C.
Chandavimol M.
Ewe S.H.
Yin W.H.
Lee Y.T.
Tay E.L.
Poon K.
Chen M.
Chui A.
Lam S.C.C.
Rao R.S.
Izumo M.
Nair R.
Tang G.H.
Tabata M.
Yahaya S.A.
Sin K.Y.
Park D.W.
Wang J.
Chieh J.T.W.
Author's Affiliation
Sengkang General Hospital
Tokyo Bay Urayasu Ichikawa Medical Center
Ramathibodi Hospital
Siriraj Hospital
National Yang Ming Chiao Tung University
The Second Affiliated Hospital Zhejiang University School of Medicine
Cheng Hsin General Hospital
Duke-NUS Medical School
West China School of Medicine/West China Hospital of Sichuan University
Hanoi Medical University
Asan Medical Center
Queen Mary Hospital Hong Kong
National University Hospital
The University of Queensland
Keio University School of Medicine
Fortis Escorts Heart Institute & Research Centre
Institut Jantung Negara Kuala Lumpur
Seoul National University Hospital
Monash University
Nelson Hospital
Sinai Health System
Queen Elizabeth Hospital Hong Kong
St. Marianna University School of Medicine
Liverpool Hospital
National Heart Centre Singapore
Zhejiang University
The Prince Charles Hospital
State Key Laboratory of Transvascular Implantation Devices
Cardiovascular Key Laboratory of Zhejiang Province
Asian Heart & Vascular Centre
Rajasthan Hospital
Chinese General Hospital and Medical Center
Vietnam National Heart Institute
Tokyo Bay Urayasu Ichikawa Medical Center
Ramathibodi Hospital
Siriraj Hospital
National Yang Ming Chiao Tung University
The Second Affiliated Hospital Zhejiang University School of Medicine
Cheng Hsin General Hospital
Duke-NUS Medical School
West China School of Medicine/West China Hospital of Sichuan University
Hanoi Medical University
Asan Medical Center
Queen Mary Hospital Hong Kong
National University Hospital
The University of Queensland
Keio University School of Medicine
Fortis Escorts Heart Institute & Research Centre
Institut Jantung Negara Kuala Lumpur
Seoul National University Hospital
Monash University
Nelson Hospital
Sinai Health System
Queen Elizabeth Hospital Hong Kong
St. Marianna University School of Medicine
Liverpool Hospital
National Heart Centre Singapore
Zhejiang University
The Prince Charles Hospital
State Key Laboratory of Transvascular Implantation Devices
Cardiovascular Key Laboratory of Zhejiang Province
Asian Heart & Vascular Centre
Rajasthan Hospital
Chinese General Hospital and Medical Center
Vietnam National Heart Institute
Corresponding Author(s)
Other Contributor(s)
Abstract
Transcatheter aortic valve implantation (TAVI) has been established as an effective treatment modality in patients with severe aortic stenosis (AS) and the uptake of TAVI is rapidly growing in the Asia-Pacific region. However, there exist a heterogeneity in the management of aortic stenosis and the use of TAVI among countries in the region. Reasons for these differences include anatomic variations, disparity in healthcare resources and infrastructure, and the lack of consensus on the optimal management of AS in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group, including a multidisciplinary group of general and interventional cardiologists, cardiac surgeons, imaging specialists, developed a position statement on the recommendations for TAVI in the management of aortic stenosis. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of “agree” or “neutral.” The resulting 28 statements provide guidance for clinical practitioners in the region on the use of TAVI in the treatment of patients with aortic stenosis.